Jung Choi, MBA

Jung is the chief executive officer of Alterome. She is passionate about delivering life-changing benefits for patients and their families through the discovery and development of transformative medicines. Jung has led at the intersection of science and business for over two decades. As chief business and strategy officer for Global Blood Therapeutics (GBT), she led corporate and business development, corporate strategy, R&D program leadership and management, patient advocacy, and government affairs and policy. She was instrumental in effectively scaling GBT from preclinical stage to commercialization, building an innovative pipeline, and leading GBT’s $5.4B acquisition by Pfizer. Prior to GBT, she served as senior vice president, corporate development, for InterMune (acquired by Roche) and Chimerix. She held various management positions of increasing responsibility at Gilead Sciences, including leadership of business development, licensing and mergers and acquisition activities, and marketing director leading the US commercial launch of Hepsera. She was vice president at Bay City Capital and an engagement manager at McKinsey & Company. During her career, Jung has led or managed over 50 transactions exceeding $17 billion in value. Jung was an entrepreneur-in-residence at Third Rock Ventures and currently serves on the board of directors of Annexon Biosciences and New York Blood Center. She is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership Network. Jung received a BA in human biology and an MBA from Stanford University.